Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2022 Earnings Call Transcript

Mark Goldsmith: Yes. Thanks, Jay. Maybe just to take the last part of your question first. Adagrasib is a big gorilla drug in the field today, it’s used by everybody in first-line therapy for lung cancer in particular. And I don’t think the fact that it’s dosed parenterally really causes a challenge for anybody. So I’m not sure that we’re aware of the need for an oral agent. So that’s my first comment. I don’t know, Steve he’s agreeing with that. And then with regard to Miratia’s study, it’s interesting. We always are interested to see what other people go do. It doesn’t really change much. I don’t think being successful with an oral agent will give them any particular advantage over being successful with KEYTRUDA. Maybe your last question was a much bigger question which is what are all the possible things we might combine within the immunology field or elsewhere, again, KEYTRUDA is the big gorilla.

And doctors are used to using it. It’s well-established; there’s a lot of data to support it. So I think it is important, particularly in immune-responsive tumors, like lung cancer to find a way to combine with an anti-PD-1 and the most well-validated antibody is KEYTRUDA, although there are others that are active as well. We’re very interested in going beyond that but everything else beyond that is pretty exploratory at this point. And I think can’t be considered a primary account. I’d say stay tuned. But for the moment, I think it’s very well-defined what one needs to do to get your drug in front of the right patients.

Operator: As there are no more questions in the queue, I’d like to turn the call back to Dr. Goldsmith for closing remarks.

Mark Goldsmith: Thank you, operator and thank you to everyone for participating today. We appreciate your support of Revolution Medicines.

Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect. Everyone, have a wonderful day.